Therapeutic Advances in Musculoskeletal Disease : Impact Factor & More
eISSN: 1759-7218pISSN: 1759-720X
Open AccessShare this on:
Key Metrics
CiteScore 
3.7
H-Index
44
Impact Factor
< 5
SJR
Q1Rheumatology
SNIP
1.17
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Therapeutic Advances in Musculoskeletal Disease
Therapeutic Advances in Musculoskeletal Disease Journal Specifications
| Overview | |
| Publisher | SAGE PUBLICATIONS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2300 |
| Publication Time | 18 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2009 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Therapeutic Advances in Musculoskeletal Disease ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Therapeutic Advances in Musculoskeletal Disease
Underestimation of fracture risk by conventional FRAX thresholds in axial spondyloarthritis: a proposal for disease-specific thresholds
- 15 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Efficacy and safety of dual-targeted therapy with tofacitinib and TNF inhibitors in refractory spondyloarthritis: a case series from a tertiary care center
- 13 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Effectiveness and safety of neridronate in chronic nonbacterial osteomyelitis: insight from the CAMELOT registry
- 11 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Real-world performance of EULAR and GRAPPA definitions of difficult-to-treat psoriatic arthritis within the ORCHESTRA cohort: an observational cohort study
- 7 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Long-term dynamic of muscle mass and its effectors in female patients with rheumatoid arthritis: a 5-year prospective cohort study
- 5 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Stakeholder perspectives on musculoskeletal pain assessment and management in the UK: a qualitative study
- 1 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Underestimation of fracture risk by conventional FRAX thresholds in axial spondyloarthritis: a proposal for disease-specific thresholds
- 15 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Efficacy and safety of dual-targeted therapy with tofacitinib and TNF inhibitors in refractory spondyloarthritis: a case series from a tertiary care center
- 13 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Effectiveness and safety of neridronate in chronic nonbacterial osteomyelitis: insight from the CAMELOT registry
- 11 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Real-world performance of EULAR and GRAPPA definitions of difficult-to-treat psoriatic arthritis within the ORCHESTRA cohort: an observational cohort study
- 7 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Long-term dynamic of muscle mass and its effectors in female patients with rheumatoid arthritis: a 5-year prospective cohort study
- 5 May 2026
- Therapeutic Advances in Musculoskeletal Disease
Stakeholder perspectives on musculoskeletal pain assessment and management in the UK: a qualitative study
- 1 May 2026
- Therapeutic Advances in Musculoskeletal Disease
FAQs on Therapeutic Advances in Musculoskeletal Disease
How long has Therapeutic Advances in Musculoskeletal Disease been actively publishing? 
What is the publishing frequency of Therapeutic Advances in Musculoskeletal Disease?
How many articles did Therapeutic Advances in Musculoskeletal Disease publish last year?
What is the eISSN & pISSN for Therapeutic Advances in Musculoskeletal Disease?
What is Citescore for Therapeutic Advances in Musculoskeletal Disease?
What is the H Index for Therapeutic Advances in Musculoskeletal Disease ?
What is SNIP score for Therapeutic Advances in Musculoskeletal Disease?
What is the SJR for Therapeutic Advances in Musculoskeletal Disease?
Who is the publisher of Therapeutic Advances in Musculoskeletal Disease?
